Logo image of FDA.MI

FIDIA SPA (FDA.MI) Stock Fundamental Analysis

BIT:FDA - Euronext Milan - IT0001498481 - Common Stock - Currency: EUR

0.0098  0 (-5.77%)

Fundamental Rating

1

FDA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 105 industry peers in the Machinery industry. Both the profitability and financial health of FDA have multiple concerns. FDA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

FDA had negative earnings in the past year.
FDA had a negative operating cash flow in the past year.
FDA had negative earnings in 4 of the past 5 years.
Of the past 5 years FDA 4 years had a positive operating cash flow.
FDA.MI Yearly Net Income VS EBIT VS OCF VS FCFFDA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

1.2 Ratios

FDA has a worse Return On Assets (-20.98%) than 82.69% of its industry peers.
Looking at the Return On Equity, with a value of -146.48%, FDA is doing worse than 89.42% of the companies in the same industry.
Industry RankSector Rank
ROA -20.98%
ROE -146.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FDA.MI Yearly ROA, ROE, ROICFDA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

With an excellent Gross Margin value of 63.26%, FDA belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
In the last couple of years the Gross Margin of FDA has grown nicely.
The Profit Margin and Operating Margin are not available for FDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.25%
GM growth 5Y2.87%
FDA.MI Yearly Profit, Operating, Gross MarginsFDA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

0

2. Health

2.1 Basic Checks

FDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for FDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FDA.MI Yearly Shares OutstandingFDA.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 1M 2M 3M 4M 5M
FDA.MI Yearly Total Debt VS Total AssetsFDA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M

2.2 Solvency

FDA has an Altman-Z score of 0.18. This is a bad value and indicates that FDA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.18, FDA is doing worse than 72.12% of the companies in the same industry.
FDA has a Debt/Equity ratio of 1.46. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.46, FDA is not doing good in the industry: 81.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Altman-Z 0.18
ROIC/WACCN/A
WACC8.32%
FDA.MI Yearly LT Debt VS Equity VS FCFFDA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M 15M

2.3 Liquidity

A Current Ratio of 0.99 indicates that FDA may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.99, FDA is doing worse than 83.65% of the companies in the same industry.
A Quick Ratio of 0.41 indicates that FDA may have some problems paying its short term obligations.
The Quick ratio of FDA (0.41) is worse than 92.31% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.41
FDA.MI Yearly Current Assets VS Current LiabilitesFDA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 69.28% over the past year.
The Revenue has grown by 21.40% in the past year. This is a very strong growth!
Measured over the past years, FDA shows a very negative growth in Revenue. The Revenue has been decreasing by -13.11% on average per year.
EPS 1Y (TTM)69.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.52%
Revenue 1Y (TTM)21.4%
Revenue growth 3Y10.44%
Revenue growth 5Y-13.11%
Sales Q2Q%4.81%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FDA.MI Yearly Revenue VS EstimatesFDA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
FDA.MI Yearly EPS VS EstimatesFDA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 0.5 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FDA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDA.MI Price Earnings VS Forward Price EarningsFDA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FDA.MI Per share dataFDA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

FDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIDIA SPA

BIT:FDA (3/7/2025, 7:00:00 PM)

0.0098

0 (-5.77%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.04%
Inst Owner ChangeN/A
Ins Owners7.31%
Ins Owner ChangeN/A
Market Cap450.60K
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.13
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.63
BVpS0.1
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.98%
ROE -146.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.26%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.25%
GM growth 5Y2.87%
F-Score2
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.45%
Cap/Sales 2.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.41
Altman-Z 0.18
F-Score2
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)18.48%
Cap/Depr(5y)22.49%
Cap/Sales(3y)1.08%
Cap/Sales(5y)1.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.52%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)21.4%
Revenue growth 3Y10.44%
Revenue growth 5Y-13.11%
Sales Q2Q%4.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1173.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-709.96%
OCF growth 3YN/A
OCF growth 5YN/A